



ROB RODRIGUES

Partner

+55 21 3550 3723

+55 21 99813 4328

roberto.rodrigues@lickslegal.com

PRACTICE AREAS

- Patents
- Copyright
- Trade Secrets & Regulatory
- Data Protection
- Licensing & Technology Transfer
- Internet, E-commerce & Software
- Food & Drug Law

LANGUAGES

- Portuguese
- English
- Spanish

BIOGRAPHY

Rob Rodrigues manages high-stakes business and intellectual property disputes in Brazil. He offers unmatched expertise to both FORTUNE 500 giants and agile startups, navigating the intricate landscape of high-complexity cases with a strategic finesse. His management of extensive patent portfolios for leading life sciences and telecommunications firms underscores his deep understanding of the Brazilian market, making him the primary choice for acquisition and enforcement endeavors.

Rob's partnership approach ensures that clients' patent portfolios are meticulously developed and maintained. He aligns patent strategies with regulatory requirements, solidifying dominant stances throughout Latin America. His proficiency extends to defensive roles in due diligence analysis and Freedom to Operate (FTOs), as well as addressing IP considerations in transactional contexts.

Having spearheaded multiple preliminary injunction proceedings and trials for global companies in Brazil, Rob's litigation acumen shines. He also facilitates monumental IP asset transactions, with a keen eye on managing transnational risks. Commendations from clients highlight his unparalleled technical prowess, resilience under pressure, and exceptional local leadership.

Currently, Rob is steering complex multijurisdictional cases for pioneering Brazilian companies, showcasing his technical ability in advising on both local IP strategies and international arbitration.

Esteemed publications, including The Legal 500, Strategy 300, and IP Stars, consistently recognize Rob's excellence. Client testimonials laud him for his "remarkable ability in handling intricate M&A transactions," praising his blend of "technical brilliance, commercial insight, and judicious decision-making."

A Stanford Law School LL.M. alumnus, Rob served as the lead editor of the Stanford Technology Law Review. He has contributed extensively to global technology law journals and currently holds an editorial role at the Kluwer IP Blog.

REPRESENTATIVE CASES

- Trial associate for biopharmaceutical company in patent enforcement against biosimilar companies;
- Associate for startup company in defense of abusive behavior action;
- Counsel for pharmaceutical company in an antitrust case involving sham litigation claims.

PROFESSIONAL HIGHLIGHTS

- Who's Who Legal – Life Sciences - Patent Litigation (2024);
- Chambers Brazil Contentious – Intellectual Property – Patent (2024);
- IAM Strategy 300 Global Leaders (2024);
- The Legal 500 Latin America – Intellectual Property (2024, 2023);
- The Legal 500 Latin America – Life Sciences (2024, 2022);
- Lexology – Legal Influencer: Dispute Resolution Q2 and Q3 (2023);
- IP Stars – Notable Practitioner (2023, 2022, 2021);
- IAM Strategy 300 (2023);
- Lexology – Legal Influencer: Dispute Resolution (2023);
- WIPR Leaders (2023);
- IAM Patent 1000 – Patent Litigation (2023);
- Leaders League – Life Sciences (2023, 2022);
- Leaders League – Patent Prosecution (2023);
- IP Stars – Rising Star (2019).

AFFILIATIONS

- Brazilian Bar Association – Rio de Janeiro Section (OAB/RJ);
- Vice-Chair LATAM Committee IPO.

EDUCATION

- Stanford Law School (LLM in Law, Science and Technology 2017);
- Stanford Technology Law Review: lead editor;
- Hoover IP2 Summer Teaching Institute – Residential Scholarship (2017);
- Bachelor of Laws (LL.B), Universidade Federal do Rio de Janeiro (2013).

PUBLICATIONS

- [Green Patents: encouraging sustainable innovation in Brazil](#), Kluwer Patent Blog, 2024;
- [Columbia Law School: Brazil Forum - Challenges and Perspectives](#), JOTA, 2024;
- [Boom in Brazil's Medical Device Market Creates Patent Infringement Issue](#), IPWatchDog, 2024;
- [Vaccines in Development](#), Genetic Engineering & Biotechnology News, 2024;
- [Computadores quânticos e IA: novos desafios judiciais](#), Valor Econômico, 2024;

- [VIP Community on Path to Patents in Brazil, Comma Matters, and DOCX-related Errors](#), Voice of IP, 2024;
- [Divulgação do programa nacional Mover traz expectativas para o aumento de depósitos de patentes voltadas à tecnologia verde](#), Migalhas, 2024;
- [Animal Health and Patent Litigation](#), Kluwer Patent Blog, 2024;
- [Elon Musk x OpenAI: o que o litígio pode significar para o futuro da IA?](#) JOTA, 2024;
- [Brazilian Lawmaker Introduces Bill to Allow AI as Inventor](#), IP Watchdog, 2024;
- [Brazil – Important updates on the new rules regulating administrative appeals](#), Kluwer Patent Blog, 2024;
- [Brazilian Congressman introduces bill to allow AI as inventor](#), Kluwer Patent Blog, 2024;
- [Congresso vai discutir se IA pode ser inventora de pedido de patente](#), JOTA, 2024;
- [Artificial Intelligence and Quantum Computers are coming - with legal challenges](#), Chambers, 2024;
- [Patent filings and divisionals in Brazil: The challenge to obtain IP protection](#), Kluwer Patent Blog, 2024;
- [BRPTO latest efforts on harmonization and Fighting the backlog](#), Chambers, 2024;
- [Brazil – BRPTO violates due process and publishes rules impacting appeals and patent examination](#), Kluwer Patent Blog, 2024;
- [Brazil to introduce skinny labels for generic drugs](#), IAM, 2023;
- [ANVISA approves skinny labeling in Brazil](#), Kluwer Patent Blog, 2023;
- [Brazilian Supreme Court issues new guidance on landmark patent term adjustment decision](#), IAM, 2023;
- [Governo relança PDPs, preocupação com propriedade intelectual na indústria farmacêutica](#), Decisor Brasil, 2023;
- [Food Labeling Regulation](#), FDLI, 2023;
- [Brazilian government issues IP National Strategy guidelines for 2023-2025](#), Kluwer Patent Blog, 2023;
- [Sequence Listings In Divisional Applications – A Comparison Between The EPO and Brazilian Patent Office](#), Kluwer Patent Blog, 2023;
- [Listagem de sequências em pedidos divididos – uma comparação entre o EPO e INPI](#), Decisor Brasil, 2023;
- [Brazilian government resurrects its Partnership for Productive Development \(PDP\) program. A new threat to pharma IP rights?](#), Kluwer Patent Blog, 2023;
- [INPI lança consulta pública sobre alterações em pedidos de patente](#), JOTA, 2023;
- [Brazil: The Patent Office is Considering Changing Terms for Requesting Examination and Amending Patent Applications](#), Kluwer Patent Blog, 2023;
- [Como ter sucesso ao emendar reivindicações durante o exame de patentes no Brasil](#), Decisor Brasil, 2023;
- [The relevance of court-appointed examiners on patent cases in Brazil](#), Kluwer Patent Blog, 2023;
- [Brasil torna-se um fórum relevante para litígios de patentes de telecomunicações](#), Decisor Brasil, 2023;
- [Brazil: how to successfully amend claims during patent examination](#), Kluwer Patent Blog, 2023;
- [Anotação de patente: repercussões de recente decisão da Justiça Federal do Rio de Janeiro](#), Decisor Brasil, 2023;
- [Brazil Becoming Relevant Forum for Telecom Patent Litigation](#), IPWatchDog, 2023;
- [Brazil implements changes to facilitate the recordal of IP agreements](#), Kluwer Patent Blog, 2023;
- [Justiça suspende decisão do INPI sobre solado vermelho da Louboutin](#), Valor Econômico, 2023;
- [BRPTO New Report on 5G Patent Applications in Brazil](#), Kluwer Patent Blog, 2023;
- [Annotation of patents: a threat to second medical use patents in Brazil?](#), Kluwer Patent Blog, 2023;
- [Reivindicações de produto por processo no Brasil: como obter reivindicações efetivas?](#), Decisor Brasil, 2023;

- [Dupla proteção patentária e a prática brasileira de patentes](#), Decisor Brasil, 2023;
- [A Amazônia em destaque: Uma oportunidade para a biotecnologia no Brasil](#), Decisor Brasil, 2023;
- [Bacteriophages and the Pressing Problem of Antibiotic Resistance](#), Genetic Engineering & Biotechnology News, 2023;
- [UPC registra 19 ações no dia de lançamento, incluindo a infração de patente unitária](#), Migalhas, 2023;
- [Patente unitária começa a valer em 17 países da União Europeia, Valor Econômico, 2023;](#)
- [Patent Term Adjustment in Brazil at the centre of major battle for IP owners](#), IAM, 2023;
- [Ajuste do Prazo de Patentes no Brasil: visão geral da discussão em curso no Judiciário](#), Decisor Brasil, 2023;
- [Brazil – Christian Louboutin victory protects red sole as “unregistered” design IP](#), Wolters Kluwer, 2023;
- [Justiça de São Paulo reconhece sapato com sola vermelha como marca da francesa Christian Louboutin](#), O Globo, 2023;
- [Double patenting and the Brazilian patent practice](#), Kluwer Patent Blog, 2023;
- [Product-by-process claims in Brazil: how to obtain effective claims?](#), Kluwer Patent Blog, 2023;
- [Brazil: Christian Louboutin succeeds with unregistered rights](#), IP Stars, 2023;
- [Brasil tem aumento de depósitos no Escritório Europeu de Patentes \(EPO\) em 2022](#), Migalhas, 2023;
- [Brazil: leading case allows revival of a patent application](#), Kluwer Patent Blog, 2023;
- [Skinny label in Brazil: drug authority seeking to implement new regulations](#), Kluwer Patent Blog, 2023;
- [The Amazon in the Limelight: An Opportunity for Biotech in Brazil](#), Genetic Engineering & Biotechnology News, 2023;
- [Comments on Joint USPTO-FDA Collaboration Initiatives](#), Intellectual Property Owners Association (IPO), 2023;
- [Startup valuation e cuidado com ativos intelectuais](#), Valor Econômico, 2023;
- [Patenting antibody-related inventions in Brazil](#), IP Stars, 2023;
- [Brazilian patent term decision quashed and other 2022 Latin America developments](#), IAM, 2023;
- [Indústria de genéricos usa prática ilegal no Brasil para alterar bulas e infringir patentes](#), Migalhas, 2022;
- [Brazilian Supreme Court gives hope companies facing shortened patent terms](#), IAM, 2022;
- [Biomedical R&D in Brazil: who owns IP rights?](#), The Legal 500, 2022;
- [Framework for Analysis of Venue Selection for Global Patent Litigation: Strategic Considerations](#), The Sedona Conference, 2022;
- [German Federal Court opens door more document transparency patent cases](#), JUVE Patent, 2022;
- [Biomedical Innovation in Brazil: an update](#), Bioengineering, 2022;
- [An overview of post-grant opposition procedure in Brazil](#), IP Stars, 2022;
- [How Brazil is becoming a more favourable jurisdiction for life sciences patentees](#), IAM, 2022;
- [Biotechnology/pharma patent litigation in Brazil: an update on preliminary injunctions](#), Kluwer Patent Blog, 2022;
- [Post-filing experimental evidence: how to obtain patents in Brazil?](#), Kluwer Patent Blog, 2022;
- [Bolsonaro vetoes Brazil’s first-of-a-kind compulsory tech transfer law](#), IAM, 2021;
- [Brazil’s patent term decision: impact and practical tips](#), IP Stars, 2021;
- [Brazilian Supreme Court considers ruling on patent case for the first time in this century](#), Journal of Intellectual Property Law & Practice, 2021;
- [Thousands of patents at risk of cancellation in Brazil](#), IAM, 2021;
- [Brazilian Supreme Court Sets an earlier date to decide the fate on the 10-Year Patent Term](#), BRICS and Beyond, 2021;

- [Em pedido ao STF, PGR mira Covid-19, mas acerta na economia nacional](#), JOTA, 2021;
- [A lição chinesa para a inovação](#), Estadão, 2020;
- [Google: um monopólio global imbatível no mercado de buscas?](#), Estadão, 2020;
- [A estreia da propriedade intelectual no STF: ADI 5529 e seus impactos sistêmicos](#), JOTA, 2020;
- [COVID-19: The impact on IP law and practice in Brazil](#), IP Stars, 2020;
- [L'INPI brésilien réussit son pari: les demandes de brevet enfin examinées](#), Lexis 360, 2020;
- [Brazil: New Regulation of Cannabis-Based Drugs Coming Soon](#), FDLI, 2019;
- [Brazil: Pharmacovigilance Risk in Evolving Biosimilar Regulation](#), FDLI, 2015;
- Co-author: [New Regulation of Cannabis-Based Drugs Coming Soon](#) (Update Magazine, a publication of the Food and Drug Law Institute (FDLI), November/December 2019);
- [Breaking through asphalt](#), Bioengineering, 2018;
- [Miller, Shawn P. and Aravind, Ashwin and Bengfort, Bethany and De La Cerda, Clarisse and Dragoni, Matteo and Gibson, Kevin and Itai, Amit and Johnson, Charles and Kannappan, Deepa and Kehoe, Emily and Kim, Hyosang and Mladinich, Katherine and Pinho, Roberto and Polansky, John and Weissenberg, Brian, Who's Suing Us? Decoding Patent Plaintiffs since 2000 with the Stanford NPE Litigation Dataset \(July 18, 2018\). Stanford Technology Law Review, Vol. 21, No. 234, 2018;](#)
- [Enforcing pending patent applications in Brazil: a different approach to dealing with the backlog \(12, 2017 publication descriptionOxford Journal of Intellectual Property Law & Practice\);](#)
- Co-author: [“Gauging the Future of Biosimilars in Brazil: Looking Ahead after the Approval of the Monoclonal Remsima” \(GEN Exclusives, 2015\) \(http://www.genengnews.com/public/AnalysisAndInsight/item.aspx?id=77900537&a=false\);](#)
- Co-author: [“Patent Knowledge Share: Brazil” \(The Patent Lawyer Magazine, September/October 2015\);](#)
- Co-author: [“The Business of Immuno-Oncology” \(http://www.genengnews.com/gen-exclusives/the-business-of-immuno-oncology/77900600\);](#)
- Author: [“Brazil: Pharmacovigilance Risk in Evolving Biosimilar Regulation” \(Update Magazine, a publication of the Food and Drug Law Institute \(FDLI\), March/April 2015\).](#)

SPEAKING ENGAGEMENTS AND OTHERS

- [Columbia Law School: Brazil Forum - Challenges and Perspectives](#) (2024, April 12);
- [Sedona Conference on Global Intellectual Property Litigation](#) (2024, March 5-6);
- [FCBA Global Series](#) (2023, November 1-3);
- [IPO 2023 Annual Meeting](#) (2023, September 10-12);
- [FCBA Bench & Bar](#) (2023, June 30);
- [IPWatchDog - Patent Prosecution & Portfolio Management Masters](#) (2023, June 20-21);
- [Sedona Conference on Global Intellectual Property Litigation](#) (2023, January 9-10).